Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
出版年份 2021 全文链接
标题
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-12-20
DOI
10.3389/fphar.2021.766125
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
- (2021) Benedetta Maria Bonora et al. Cardiovascular Diabetology
- Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
- (2021) Avivit Cahn et al. DIABETES CARE
- Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines
- (2021) Stefano Ciardullo et al. PHARMACOLOGICAL RESEARCH
- Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
- (2021) Thomas M. Caparrotta et al. Diabetes Therapy
- Effects of SGLT2 inhibitor on ischemic events stemming from atherosclerotic coronary diseases
- (2021) Gailin Ye et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
- (2020) Tongtong Wang et al. Diabetes Therapy
- Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study
- (2020) Christie Rampersad et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
- (2020) Vikas S. Sridhar et al. DIABETES OBESITY & METABOLISM
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
- (2020) Antonios Douros et al. ANNALS OF INTERNAL MEDICINE
- Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
- (2020) Yang Hu et al. Journal of Diabetes Research
- Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits
- (2020) Kristen Jackson et al. Current Osteoporosis Reports
- SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
- (2020) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- An update on the safety of SGLT2 inhibitors
- (2019) André J Scheen Expert Opinion On Drug Safety
- Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
- (2019) Zien Zhou et al. DIABETOLOGIA
- Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
- (2019) Yinghong Zhai et al. Journal for ImmunoTherapy of Cancer
- Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
- (2019) Gian Paolo Fadini et al. BMJ Open Diabetes Research & Care
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
- (2019) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- (2018) Robert Puckrin et al. ACTA DIABETOLOGICA
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems
- (2017) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- (2017) Gian Paolo Fadini et al. Lancet Diabetes & Endocrinology
- SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
- (2016) Hiroyuki Ito et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cerebral infarction and femoral venous thrombosis detected in a patient with diabetic ketoacidosis and heterozygous factor V Leiden G1691A and PAI-1 4G/5G mutations
- (2015) Selcen Yaroglu Kazanci et al. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
- (2011) Jean-Louis Montastruc et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
- (2011) G Niklas Norén et al. STATISTICAL METHODS IN MEDICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now